126 related articles for article (PubMed ID: 22023068)
1. Resource utilization before and during infliximab therapy in patients with inflammatory bowel disease.
Waters HC; Vanderpoel JE; Nejadnik B; McKenzie RS; Lunacsek OE; Lennert BJ; Goff J; Augustyn DH
J Med Econ; 2012; 15(1):45-52. PubMed ID: 22023068
[TBL] [Abstract][Full Text] [Related]
2. Stability of infliximab dosing in inflammatory bowel disease: results from a multicenter US chart review.
Waters H; Vanderpoel J; McKenzie S; Lunacsek O; Franklin M; Lennert B; Goff J; Augustyn DH
J Med Econ; 2011; 14(4):397-402. PubMed ID: 21595522
[TBL] [Abstract][Full Text] [Related]
3. Dual therapy with infliximab and immunomodulator reduces one-year rates of hospitalization and surgery among veterans with inflammatory bowel disease.
Abraham NS; Richardson P; Castillo D; Kane SV
Clin Gastroenterol Hepatol; 2013 Oct; 11(10):1281-7. PubMed ID: 23792295
[TBL] [Abstract][Full Text] [Related]
4. A review of infliximab use in ulcerative colitis.
Wilhelm SM; McKenney KA; Rivait KN; Kale-Pradhan PB
Clin Ther; 2008 Feb; 30(2):223-30. PubMed ID: 18343261
[TBL] [Abstract][Full Text] [Related]
5. Impact of infliximab adherence on Crohn's disease-related healthcare utilization and inpatient costs.
Carter CT; Waters HC; Smith DB
Adv Ther; 2011 Aug; 28(8):671-83. PubMed ID: 21818671
[TBL] [Abstract][Full Text] [Related]
6. Impact of persistence with infliximab on hospitalizations in ulcerative colitis.
Carter CT; Leher H; Smith P; Smith DB; Waters HC
Am J Manag Care; 2011 Jun; 17(6):385-92. PubMed ID: 21756009
[TBL] [Abstract][Full Text] [Related]
7. Careful patient selection may improve response rates to infliximab in inflammatory bowel disease.
Pearce CB; Lawrance IC
J Gastroenterol Hepatol; 2007 Oct; 22(10):1671-7. PubMed ID: 17845695
[TBL] [Abstract][Full Text] [Related]
8. CD40 and CD86 upregulation with divergent CMRF44 expression on blood dendritic cells in inflammatory bowel diseases.
Vuckovic S; Florin TH; Khalil D; Zhang MF; Patel K; Hamilton I; Hart DN
Am J Gastroenterol; 2001 Oct; 96(10):2946-56. PubMed ID: 11693331
[TBL] [Abstract][Full Text] [Related]
9. Safety and effectiveness of infliximab for inflammatory bowel diseases in clinical practice.
Tursi A; Elisei W; Brandimarte G; Giorgetti G; Penna A; Castrignano V
Eur Rev Med Pharmacol Sci; 2010 Jan; 14(1):47-55. PubMed ID: 20184089
[TBL] [Abstract][Full Text] [Related]
10. Infliximab therapy downregulation of basic fibroblast growth factor/syndecan 1 link: a possible molecular pathway of mucosal healing in ulcerative colitis.
Ierardi E; Giorgio F; Zotti M; Rosania R; Principi M; Marangi S; Della Valle N; De Francesco V; Di Leo A; Ingrosso M; Panella C
J Clin Pathol; 2011 Nov; 64(11):968-72. PubMed ID: 21945924
[TBL] [Abstract][Full Text] [Related]
11. Adherence to infliximab maintenance therapy and health care utilization and costs by Crohn's disease patients.
Kane SV; Chao J; Mulani PM
Adv Ther; 2009 Oct; 26(10):936-46. PubMed ID: 19838649
[TBL] [Abstract][Full Text] [Related]
12. Inflammatory bowel disease in the United States from 1998 to 2005: has infliximab affected surgical rates?
Cannom RR; Kaiser AM; Ault GT; Beart RW; Etzioni DA
Am Surg; 2009 Oct; 75(10):976-80. PubMed ID: 19886148
[TBL] [Abstract][Full Text] [Related]
13. Preoperative infliximab therapy does not increase morbidity and mortality after laparoscopic resection for inflammatory bowel disease.
Krane MK; Allaix ME; Zoccali M; Umanskiy K; Rubin MA; Villa A; Hurst RD; Fichera A
Dis Colon Rectum; 2013 Apr; 56(4):449-57. PubMed ID: 23478612
[TBL] [Abstract][Full Text] [Related]
14. Infliximab maintenance therapy is associated with decreases in direct resource use in patients with luminal or fistulizing Crohn's disease.
Taxonera C; Rodrigo L; Casellas F; Calvet X; Gómez-Camacho F; Ginard D; Castro M; Castro L; Ponce M; Martínez-Montiel P; Ricart E; Gisbert JP; López-San Román A; Morales JM; Casado MA
J Clin Gastroenterol; 2009; 43(10):950-6. PubMed ID: 19448569
[TBL] [Abstract][Full Text] [Related]
15. Infliximab use in luminal Crohn's disease.
Richter JA; Bickston SJ
Gastroenterol Clin North Am; 2006 Dec; 35(4):775-93. PubMed ID: 17129813
[TBL] [Abstract][Full Text] [Related]
16. Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort.
Frøslie KF; Jahnsen J; Moum BA; Vatn MH;
Gastroenterology; 2007 Aug; 133(2):412-22. PubMed ID: 17681162
[TBL] [Abstract][Full Text] [Related]
17. Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis.
Colombel JF; Rutgeerts P; Reinisch W; Esser D; Wang Y; Lang Y; Marano CW; Strauss R; Oddens BJ; Feagan BG; Hanauer SB; Lichtenstein GR; Present D; Sands BE; Sandborn WJ
Gastroenterology; 2011 Oct; 141(4):1194-201. PubMed ID: 21723220
[TBL] [Abstract][Full Text] [Related]
18. [Management of failure of infliximab in inflammatory bowel disease].
Naija N; Karoui S; Serghini M; Kallel L; Boubaker J; Filali A
Tunis Med; 2011 Jun; 89(6):517-21. PubMed ID: 21681712
[TBL] [Abstract][Full Text] [Related]
19. [Infliximab therapy for Crohn's disease - a practical guideline: actualised consensus of the working group for chronic inflammatory bowel diseases of the Austrian Society for Gastroenterology and Hepatology].
Reinisch W; Dejaco C; Feichtenschlager T; Haas T; Kaser A; Miehsler W; Novacek G; Petritsch W; Platzer R; Tilg H; Vogelsang H; Knoflach P;
Z Gastroenterol; 2011 Apr; 49(4):534-42. PubMed ID: 21442574
[TBL] [Abstract][Full Text] [Related]
20. Disease course and surgery rates in inflammatory bowel disease: a population-based, 7-year follow-up study in the era of immunomodulating therapy.
Vester-Andersen MK; Prosberg MV; Jess T; Andersson M; Bengtsson BG; Blixt T; Munkholm P; Bendtsen F; Vind I
Am J Gastroenterol; 2014 May; 109(5):705-14. PubMed ID: 24642581
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
